{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:34:53Z","timestamp":1786977293487,"version":"build-2736575974"},"reference-count":73,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Brain and Behavior"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A third of epilepsy patients fail to enter seizure remission despite optimal therapeutic management. Cannabis\u2010based medicinal products (CBMPs) have shown promise as a potential therapy. However, a paucity of high\u2010quality literature regarding CBMPs\u2019 efficacy and safety profile means further investigation is needed. The study aimed to examine changes in epilepsy\u2010specific and general health\u2010related quality of life (HRQoL) patient\u2010reported outcome measures (PROMs) in individuals with treatment\u2010resistant epilepsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A case series of patients with epilepsy from the UK Medical Cannabis Registry analyzed changes in Quality of Life in Epilpesy\u201031 (QOILE\u201031), Single\u2010Item Sleep Quality Score (SQS), EQ\u20105D\u20105L, Generalized Anxiety Disorder\u20107 (GAD\u20107) and Patient Global Impression of Change (PGIC) between baseline, one, three, and six months. Adverse events (AEs) were collected and classified by severity.\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.050 was considered statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 134 patients included. Improvements were recorded from baseline to one, three, and six months in QOILE\u201031 and all HRQoL PROMs (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.050). Forty patients (29.85%) reported a minimal clinically important difference in Quality of Life in Epilepsy\u201031 (QOLIE\u201031) at six months. There were 18 (13.43%) AEs reported by 5 (3.73%) patients, mainly mild and moderate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The proportion of patients achieving a clinically significant change is similar to existing CBMPs in epilepsy literature. AE incidence was lower than similar studies although this may be due to the large proportion (67.16%) of individuals who were not cannabis na\u00efve.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Initiation of CBMPs was associated with an improvement across all PROMs. CBMPs were well tolerated across the cohort. However, randomized controlled trials are needed to help determine causality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1002\/brb3.70490","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T08:34:32Z","timestamp":1744965272000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Epilepsy"],"prefix":"10.1002","volume":"15","author":[{"given":"Isaac","family":"Cowley","sequence":"first","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-6501","authenticated-orcid":false,"given":"Simon","family":"Erridge","sequence":"additional","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer Imperial College London  London UK"},{"name":"Curaleaf Clinic  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushika","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5337-2620","authenticated-orcid":false,"given":"Lilia","family":"Evans","sequence":"additional","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhur","family":"Varadpande","sequence":"additional","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evonne","family":"Clarke","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"McLachlan","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Coomber","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic  London UK"},{"name":"St. George's Hospital NHS Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustin","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J","family":"Rucker","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic  London UK"},{"name":"Department of Psychological Medicine Kings College London  London UK"},{"name":"South London and Maudsley NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W","family":"Weatherall","sequence":"additional","affiliation":[{"name":"Curaleaf Clinic  London UK"},{"name":"Buckinghamshire Healthcare NHS Trust  Amersham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael H","family":"Sodergren","sequence":"additional","affiliation":[{"name":"Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer Imperial College London  London UK"},{"name":"Curaleaf Clinic  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"National Institue for Health and Care Excellence.2019.Position statement on use of the EQ\u20105D\u20105L value set for England (updated October 2019). MHRA.https:\/\/www.nice.org.uk\/about\/what\u2010we\u2010do\/our\u2010programmes\/nice\u2010guidance\/technology\u2010appraisal\u2010guidance\/eq\u20105d\u20105l[Accessed May 24 2024]."},{"issue":"3","key":"e_1_2_12_3_1","first-page":"205","article-title":"Anticonvulsant Action of Anandamide in an in Vitro Model of Epilepsy","volume":"10","author":"Al\u2010Hayani A. A.","year":"2005","journal-title":"Neurosciences (Riyadh, Saudi Arabia)"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2019.282"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2009.05.015"},{"key":"e_1_2_12_6_1","unstructured":"Barbara G. K. R. andDRon. 2024Quality of Life in Epilepsy QOLIE\u201031.https:\/\/www.rand.org\/content\/dam\/rand\/www\/external\/health\/surveys_tools\/qolie\/qolie31_scoring.pdf[Accessed May 16 2024]."},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.3c00017"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528\u20101157.2002.32201.x"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212531"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2011.12.023"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006\u20102952(93)90286\u20106"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.626853"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/medlaw\/fwaa002"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12632"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000521288"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220025"},{"key":"e_1_2_12_17_1","unstructured":"Couch D.2022.Left Behind: The Scale of Illegal Cannabis Use for Medicinal Intent in the UK.https:\/\/thecmcuk.org\/wp\u2010content\/uploads\/2022\/02\/Left\u2010Behind012020.pdf."},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528\u20101157.1998.tb01278.x"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582\u2010019\u20100284\u2010z"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2009.03.003"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476\u20105381.2010.01166.x"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2021.10.032"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51537"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13305"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1055\/a\u20102002\u20102119"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.9126"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12550"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910\u2010018\u20100882\u2010y"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.43848"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521\u20100391.2013.12003.x"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2023.12.033"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12081"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/cn5000524"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2019.01713"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11064\u2010021\u201003517\u20105"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12699"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/00207454.2023.2272042"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010018\u20100992\u20105"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.04.151"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106341"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528\u20101167.2005.00406.x"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1132106"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40429\u2010022\u201000450\u20107"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2016.1141913"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12944"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000297"},{"key":"e_1_2_12_47_1","unstructured":"National Institute of Health.2009.Common Terminology Criteria Adverse Events (CTCAE) Version 4.0.https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009\u201005\u201029_QuickReference_8.5x11.pdf."},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12006"},{"key":"e_1_2_12_49_1","unstructured":"NICE.2021.Cannabis\u2010based medicinal products.https:\/\/www.nice.org.uk\/guidance\/ng144\/chapter\/Recommendations#severe\u2010treatment\u2010resistant\u2010epilepsy[Accessed May 24 2024]."},{"key":"e_1_2_12_50_1","unstructured":"NICE.2023.Cannabidiol for treating seizures caused by tuberous sclerosis complex.https:\/\/www.nice.org.uk\/guidance\/ta873\/chapter\/1\u2010Recommendations[Accessed May 24 2024]."},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2016.11.012"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2183841"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2007.09.032"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2015.02.043"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261\u2010014\u20100212\u20103"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528\u20101167.2009.02334.x"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2012.04.017"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577501"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1590\/1806\u20109282.2022D689"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.06.083"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2016.12.032"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2017.02.005"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/15360288.2023.2174633"},{"issue":"378","key":"e_1_2_12_64_1","first-page":"1","article-title":"Symptoms of Generalized Anxiety Disorder among Adults: United States","volume":"2020","author":"Terlizzi E. P.","year":"2019","journal-title":"NCHS Data Brief"},{"key":"e_1_2_12_65_1","unstructured":"MHRA. 2020. The supply manufacture importation and distribution of unlicensed cannabis\u2010based products for medicinal use in humans \u2018specials\u2019.https:\/\/assets.publishing.service.gov.uk\/media\/5e58eefb86650c53a363f77c\/Cannabis_Guidance__unlicensed_CBPMs__updated_2020.pdf."},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13604"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072\u2010020\u201004990\u20106"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2016.01.004"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2020.06.018"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.02.008"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.3171\/2018.3.JNS171722"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102018\u2010319780"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2018.07.017"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.04.006"}],"container-title":["Brain and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.70490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T08:42:39Z","timestamp":1759135359000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/brb3.70490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/brb3.70490"],"URL":"https:\/\/doi.org\/10.1002\/brb3.70490","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/BRB3.70490\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.70490\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.70490\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.70490\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.70490\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.70490\/v1\/decision1","asserted-by":"object"}]},"ISSN":["2162-3279","2162-3279"],"issn-type":[{"value":"2162-3279","type":"print"},{"value":"2162-3279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70490"}}